Matt Miksic
Stock Analyst at Barclays
(3.89)
# 539
Out of 4,829 analysts
279
Total ratings
59.64%
Success rate
4.62%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LIVN LivaNova | Maintains: Equal-Weight | $56 → $55 | $44.06 | +24.83% | 7 | May 8, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $16 → $12 | $2.65 | +352.83% | 2 | May 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $90 → $93 | $84.67 | +9.84% | 6 | May 5, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $310.67 | -14.38% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $14.45 | +66.09% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $102.86 | +21.52% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $536.51 | +18.36% | 7 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $165 | $154.22 | +6.99% | 12 | Apr 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $158 → $159 | $133.24 | +19.33% | 29 | Apr 17, 2025 | |
| BAX Baxter International | Maintains: Overweight | $39 → $41 | $30.90 | +32.69% | 21 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $53 | $22.98 | +130.64% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $55.82 | +84.52% | 14 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $73.68 | +22.15% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $95.21 | +17.63% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $380.92 | +16.30% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $12.21 | +71.99% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.21 | +422.57% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $83.48 | +30.57% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $8.76 | +82.65% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $11.27 | +59.72% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $95.75 | +0.26% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $68.64 | +45.69% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $181.88 | +129.82% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $13.13 | +113.25% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $15.82 | +323.51% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $8.62 | +5,468.45% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.25 | +610.20% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.06 | +716.99% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.05 | +27.66% | 1 | Dec 12, 2016 |
LivaNova
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $44.06
Upside: +24.83%
Orchestra BioMed Holdings
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.65
Upside: +352.83%
DexCom
May 5, 2025
Maintains: Equal-Weight
Price Target: $90 → $93
Current: $84.67
Upside: +9.84%
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $310.67
Upside: -14.38%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $14.45
Upside: +66.09%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $102.86
Upside: +21.52%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $536.51
Upside: +18.36%
Johnson & Johnson
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $166 → $165
Current: $154.22
Upside: +6.99%
Abbott Laboratories
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $133.24
Upside: +19.33%
Baxter International
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $30.90
Upside: +32.69%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $22.98
Upside: +130.64%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $55.82
Upside: +84.52%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $73.68
Upside: +22.15%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $95.21
Upside: +17.63%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $380.92
Upside: +16.30%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $12.21
Upside: +71.99%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.21
Upside: +422.57%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $83.48
Upside: +30.57%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $8.76
Upside: +82.65%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $11.27
Upside: +59.72%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $95.75
Upside: +0.26%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $68.64
Upside: +45.69%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $181.88
Upside: +129.82%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $13.13
Upside: +113.25%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $15.82
Upside: +323.51%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $8.62
Upside: +5,468.45%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.25
Upside: +610.20%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.06
Upside: +716.99%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.05
Upside: +27.66%